Sunday - November 15, 2026
Ropes and Gray: Teva and Samsung Enter License and Commercialization Agreement for Two FDA-Approved Biosimilars in the U.S.
November 04, 2026
BOSTON, Massachusetts, Nov. 4 -- Ropes and Gray, a law firm, issued the following news:

* * *

Teva and Samsung Enter License and Commercialization Agreement for Two FDA-Approved Biosimilars in the U.S.

November 3, 2026

Ropes & Gray advised Teva Pharmaceutical Industries in a licensing and commercialization agreement with Samsung Bioepis that would give Teva U.S. rights to two FDA-approved immunology biosimilars, infliximab-abda and etanerce . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products